Cost-effectiveness of Ultrasound Screening for Uterine Fibroids in the United States

A 2026 economic evaluation using a Markov model found that annual ultrasound screening for uterine fibroids in U.S. women aged 25–54 is both cost-effective and cost-saving, potentially saving $1.169 billion annually and improving quality of life, with particularly significant benefits for Black women.

The Gist

Imagine your body is a house. For many women, uterine fibroids are like unwanted, stubborn weeds growing in the garden. Sometimes these weeds are tiny and harmless, but often they grow large, blocking pathways, causing leaks (heavy bleeding), and making the whole house uncomfortable (pain and pressure).

Currently, most women only find out they have these "weeds" when the house starts falling apart—when the pain becomes unbearable or the bleeding is uncontrollable. By then, the damage is done, and fixing it often requires a major, expensive renovation (like a hysterectomy).

This paper asks a simple but revolutionary question: What if we checked the garden every year with a simple flashlight (an ultrasound) before the weeds even became a problem?

Here is the breakdown of the study in plain English:

1. The Problem: The "Wait-and-See" Disaster

Right now, the medical rule is: "Don't check for weeds unless the house is on fire."

• The Reality: Many women suffer for years, thinking their pain is just "normal" or that they have to live with it.
• The Cost: Because they wait so long, the weeds get huge. Fixing them later is like trying to remove a giant oak tree with a chainsaw instead of pulling a small sapling with your hands. It's painful, risky, and costs the U.S. healthcare system $42.2 billion a year.
• The Inequality: For Black women, the "soil" is just more fertile for these weeds. They grow faster, bigger, and cause more trouble, yet they often face even longer waits to get help due to systemic biases in healthcare.

2. The Solution: The Annual "Garden Check-Up"

The researchers built a computer simulation (a digital crystal ball) to test what would happen if every woman aged 25 to 54 got an annual ultrasound to check for fibroids, even if they felt fine.

Think of it like checking your smoke detector every year. You don't wait for the fire to start; you check early so you can fix it before it burns the house down.

3. The Big Surprise: It's Not Just "Worth It"—It's "Free"

Usually, when you add a new medical test, it costs money. You expect the bill to go up, even if health gets better.

This study found the opposite.

• The Result: Screening women annually actually saves money.
• The Analogy: It's like buying a $50 fire extinguisher today to save you from a $50,000 house fire tomorrow.
• The Numbers: The study calculated that for every dollar spent on screening, the healthcare system saves money in the long run. In fact, if the whole U.S. did this, it could save $1.169 trillion and give women back 20.7 million years of healthy life.

4. Why Does It Save Money?

When you catch the "weeds" early:

• You don't need the chainsaw: Instead of a massive, expensive surgery (hysterectomy), doctors can use tiny, less invasive tools or even medication to shrink the problem.
• Less downtime: Women miss less work and recover faster.
• Better quality of life: Women aren't living in pain for years before getting a diagnosis.

5. The "Black Women" Factor

The study highlighted a specific group: Black women. Because they are more likely to have these fibroids and suffer more severe symptoms, the "garden check-up" is even more valuable for them.

• The Analogy: If a storm is twice as likely to hit one neighborhood, putting up storm shutters there saves twice as much damage. The study showed that screening would save Black women even more money and health than the general population.

6. The Bottom Line

The researchers concluded that we should stop waiting for the "house to catch fire" before we check for fibroids.

• Current Rule: Wait until you are in pain, then fix it (Expensive and painful).
• New Proposal: Check every year with an ultrasound (Cheap, saves money, and keeps women healthy).

In short: This paper argues that checking for fibroids annually is a "win-win." It's a small investment that prevents a massive financial and physical disaster, especially for the women who need it most. It's time to stop ignoring the weeds and start checking the garden.

Technical Summary

1. Problem Statement

Uterine fibroids are the most common benign tumors in women of reproductive age, affecting approximately 70% of White women and over 80% of Black women by age 50. They cause significant morbidity, including heavy menstrual bleeding, anemia, pain, and reproductive complications. Despite a high prevalence and an estimated annual economic burden of $42.2 billion in the U.S., current clinical guidelines do not recommend routine screening. Consequently, many women experience diagnostic delays of 3–5 years, leading to advanced disease requiring complex, invasive, and expensive surgical interventions. The study addresses the critical gap in determining whether implementing an annual ultrasound screening program for women aged 25–54 would be a cost-effective strategy to mitigate this burden.

2. Methodology

The study employed a decision-analytic Markov model to evaluate the cost-effectiveness of annual ultrasound screening compared to the current standard of care (no screening, diagnosis only upon symptom presentation).

• Study Design & Perspective: Conducted in early 2026 using a U.S. healthcare payer perspective. The analysis adhered to the CHEERS 2022 reporting standards and recommendations from the Second Panel on Cost-Effectiveness in Health and Medicine.
• Target Population: All women with a uterus aged 25–54 years in the U.S. (approx. 63.89 million), with a specific sub-analysis for Black women (approx. 9.32 million) due to their disproportionately higher prevalence and severity of fibroids.
• Time Horizon: 30 years (from age 25 to 55, covering the pre-menopausal period).
• Model Structure:
  • Health States: Fibroids Absent, Fibroids Present (Symptomatic/Asymptomatic), Fibroids Successfully Treated, and Death.
  • Strategies:
    1. Screening: Annual ultrasound starting at age 25.
    2. No Screening: Diagnosis occurs only when the patient presents with symptoms.
  • Transitions: Modeled based on probabilities of fibroid development, progression to symptomaticity, diagnosis (screening vs. clinical), treatment success/failure, and recurrence.
• Parameters & Inputs:
  • Data Sources: Variables (probabilities, costs, utilities) were derived from published literature (PubMed/Embase) and validated by six clinical specialists.
  • Costs: Adjusted to 2025 USD using the Consumer Price Index (Medical Care Index). Included direct costs of screening, treatments (medical management, UAE, HIFU, myomectomy, hysterectomy), complications, and associated conditions (anemia, preterm birth, etc.). Indirect costs (productivity loss) and infertility costs were excluded.
  • Utilities: Quality-Adjusted Life Years (QALYs) were assigned to health states, with disutilities applied for symptomatic fibroids and procedural complications.
• Analysis Techniques:
  • Base-case Analysis: Deterministic analysis to calculate the Incremental Cost-Effectiveness Ratio (ICER).
  • Sensitivity Analyses:
    • Deterministic (DSA): Univariate sensitivity analysis using Tornado diagrams to test variable uncertainty.
    • Probabilistic (PSA): Second-order Monte-Carlo simulation (10,000 trials, 1,000 samples) to assess simultaneous parameter uncertainty.
  • Thresholds: A conservative Willingness-to-Pay (WTP) threshold of $30,000 per QALY was used.

3. Key Contributions

• First Economic Evaluation of Routine Screening: This is the first study to model the cost-effectiveness of routine annual ultrasound screening for uterine fibroids in the general U.S. population, a practice currently not recommended by guidelines.
• Disparities-Conscious Analysis: The study explicitly models the Black female population as a distinct cohort, acknowledging their higher prevalence, earlier onset, and greater disease burden, thereby providing specific data to address healthcare inequities.
• Comprehensive Outcome Metrics: Beyond standard ICERs, the study quantifies the cumulative national impact in terms of total healthcare savings (billions of dollars) and total QALYs gained for the entire U.S. population.
• Age-Stratified Insights: The analysis evaluates the impact of varying the starting age of screening, demonstrating that earlier initiation yields greater economic and health benefits.

4. Results

The model demonstrated that annual ultrasound screening is a dominant strategy (both more effective and less costly) compared to no screening.

• Base-Case Economic Outcomes:
  • All Women: Screening resulted in an ICER of –$56,605.63 per QALY gained (negative ICER indicates cost-saving). The Incremental Net Monetary Benefit (INMB) was $28,001 per person.
  • Black Women: Screening was even more beneficial, with an ICER of –$60,934.86 per QALY gained and an INMB of $29,374.
• Population-Level Impact (30-Year Horizon):
  • For the 63.89 million women aged 25–54, screening could save $1.169 billion and generate 20.7 million additional QALYs.
  • For the 9.32 million Black women in this age group, screening could save $183 billion and generate 3 million additional QALYs.
• Sensitivity Analyses:
  • Robustness: The findings remained robust across a wide range of variable variations. In univariate analyses, the lowest INMB values remained positive, confirming cost-effectiveness even under extreme assumptions.
  • Key Drivers: The model was most sensitive to the probability of diagnosis without screening (i.e., the rate of diagnostic delay) and the costs associated with fibroid-related conditions.
  • Starting Age: Screening initiated at age 25 was the most cost-effective. As the starting age increased, cost-savings decreased, though screening remained cost-effective up to age 54.
  • Probabilistic Analysis: In Monte-Carlo simulations, ultrasound screening was the preferred strategy in 92.3% of trials for all women and 91.2% for Black women.

5. Significance and Implications

• Policy Recommendation: The study provides strong economic evidence to support the development and implementation of clinical guidelines recommending annual ultrasound screening for uterine fibroids in women aged 25–54.
• Clinical Impact: Early detection through screening enables secondary prevention and the use of less invasive, uterus-sparing treatments (e.g., medical management, UAE, MRgFUS) rather than waiting for symptoms to necessitate hysterectomies or complex surgeries.
• Health Equity: The findings highlight that screening is particularly vital for Black women, who bear a disproportionate burden of the disease. Implementing screening could significantly reduce racial disparities in fibroid-related morbidity and healthcare costs.
• Economic Viability: The "cost-saving" nature of the intervention suggests that healthcare payers would realize immediate financial returns through reduced long-term treatment costs, making it a highly attractive public health investment.
• Future Directions: The authors call for pilot programs to validate these model-based findings in real-world settings and to address implementation barriers such as access to ultrasound technology and provider adherence.

In conclusion, this study fundamentally challenges the current "wait-and-see" approach to uterine fibroids, demonstrating that proactive, annual ultrasound screening is not only clinically beneficial but also a financially superior strategy for the U.S. healthcare system.